Milnacipran, sold under the brand name Savella among others, is a serotonin–norepinephrine reuptake inhibitor (SNRI) used in the clinical treatment of fibromyalgia, major depressive disorder, and neuropathic pain. In the US, it is solely approved for the treatment of fibromyalgia, even though it is also approved for the treatment of major depressive disorder in other countries.
מילנסיפרן molecular structure diagram from the DrugsPRO substance library.
Also known as: Milnacipran hydrochloride, Milnacipran HCl
Classification
Chemical: Medicine
Tag: Antidepressant
Tag: SNRI
Effects
Sedation
Nausea
Headache
Increased Heart Rate
Ataxia
Stimulation
Dizziness
Euphoria
Mood Lift
Anxiety
Irritability
Focus Enhancement
Dulled Perception
Appetite Suppression
Dehydration
Internal Hallucination
Auditory Hallucination
External Hallucination
Routes of Administration
No route information available yet.
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
This static page is intended as a readable non-JS and prerender-friendly library export.
Get the full DrugsPRO experience
Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.
Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu
Milnacipran - מדריך חומרים של DrugsPRO
Milnacipran: Milnacipran, sold under the brand name Savella among others, is a serotonin–norepinephrine reuptake inhibitor (SNRI) used in the clinical treatment of fibromyalgia, major depressive disorder, and neuropathic pain. In the US, it is solely approved for the treatment of fibromyalgia, even